Evidence map›Paper›PMID 26209894›Full record

ReviewImmunology and allergy clinics of North America2015

Eosinophilia in Hematologic Disorders.

Lorenzo Falchi, Srdan Verstovsek

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Immunology and allergy clinics of North America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 32 citations in OpenAlex.

  1. Allergic symptoms in hydatid cyst; common or rare?Northern clinics of Istanbul · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. The role of eosinophils in immunotherapy.Current opinion in allergy and clinical immunology · 2020
    Article
  15. The Role of Eosinophils in Immunotherapy.Current allergy and asthma reports · 2020
    Review
  16. Diagnostic Snapshot: A Patient With Gastrointestinal Symptoms and Eosinophilia.Journal of the advanced practitioner in oncology · 2019
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Lorenzo FalchiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Srdan VerstovsekDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA. Electronic address: sverstov@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Eosinophilia in the peripheral blood can be the manifestation various medical conditions, including benign or malignant disorders. There are 3 main types of eosinophilia-associated myeloid neoplasms (MN-eos): myeloid and lymphoid neoplasms, chronic eosinophilic leukemia not otherwise specified, and idiopathic hypereosinophilic syndrome (HES). Imatinib mesylate has revolutionized the treatment of molecularly defined MN-eos, and novel agents have been successfully used to treat HES. The discovery of new, recurrent molecular alterations in patients with MN-eos may improve their diagnosis and therapy. This review focuses on the hematologist's approach to a patient with eosinophilia and treatment options for those with eosinophilic myeloid neoplasms.

Indexed as

HumansHypereosinophilic SyndromeImatinib MesylateLeukemiaLeukemia, Myelomonocytic, ChronicReceptor, Fibroblast Growth Factor, Type 1Receptor, Platelet-Derived Growth Factor alphaReceptor, Platelet-Derived Growth Factor betaImatinib MesylateReceptor, Fibroblast Growth Factor, Type 1Receptor, Platelet-Derived Growth Factor alphaReceptor, Platelet-Derived Growth Factor betaChronic eosinophilic leukemiaEosinophiliaHypereosinophilic syndromeImatinibPDGFRAPDGFRB

Identifiers

PMID26209894
PMCPMC4515577
OpenAlexW2158890026

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.